Patrick McElgunn, MD
Dermatology · Charlotte, NCNPI 1831148485
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $463,569 of the $564,620 with a category attached, or 82.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 14.6%. Among dermatology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 936 payments — averaging $603.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$82K
- AbbVie$71K
- Sanofi$65K
- Dermavant Sciences, Inc.$59K
- UCB, Inc.$44K
- Novartis$44K
- plus $199K from 29 others
Across 21 payments — averaging $52,164 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$738K
- Eli Lilly$312K
- Sanofi US Services Inc.$27K
- Taro Pharmaceuticals USA, Inc.$10K
- E.r. Squibb & Sons, L.L.C.$6K
- Amgen$2K
What the payments were for
- Consulting fees$45,1648%
- Speaking & faculty fees$463,56982%
- Travel & lodging$25,9285%
- Food & beverage$29,4185%
- Education$5410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 81 | $82,214 |
| AbbVie(2 entities) | 157 | $71,003 |
| Sanofi | 60 | $65,265 |
| Dermavant Sciences, Inc. | 53 | $58,685 |
| UCB, Inc. | 76 | $44,333 |
| Novartis | 55 | $44,234 |
| E.r. Squibb & Sons, L.L.C. | 51 | $38,221 |
| Pfizer | 83 | $37,974 |
| Regeneron Healthcare Solutions, Inc. | 84 | $35,841 |
| Amgen | 25 | $24,064 |
| Almirall LLC | 23 | $20,577 |
| Bristol Myers Squibb | 19 | $20,429 |
| Botanix SB Inc | 9 | $7,784 |
| Incyte Corporation | 6 | $3,100 |
| Johnson & Johnson | 18 | $2,773 |
| Arcutis Biotherapeutics, Inc. | 8 | $2,564 |
| Journey Medical Corporation | 13 | $1,878 |
| Sun Pharmaceutical Industries Inc. | 24 | $742 |
| Medimetriks Pharmaceuticals, Inc. | 23 | $637 |
| Promius Pharma LLC | 1 | $500 |
| LEO Pharma Inc. | 22 | $499 |
| Janssen Scientific Affairs, LLC | 5 | $449 |
| EPI Health, LLC | 13 | $332 |
| Lilly USA, LLC | 2 | $109 |
| Biofrontera Inc. | 4 | $77 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $73 |
| Strata Skin Sciences, Inc. | 4 | $64 |
| Verrica Pharmaceuticals Inc. | 3 | $45 |
| Genentech USA, Inc. | 3 | $43 |
| Mayne Pharma Commercial LLC | 2 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Organon | 1 | $23 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| DUSA Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$564,620 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $181,683 |
| TremfyaGuselkumab | 13 | $176,270 |
| Humira(Cf) PenAdalimumab | 17 | $123,621 |
| Dupixent PenDupilumab | 26 | $99,086 |
| Enbrel SureclickEtanercept | 13 | $94,196 |
| SeysaraSarecycline Hcl | 11 | $11,078 |
| Doxycycline Hyclate | 177 | $6,829 |
| Betamethasone Dipropionate | 193 | $6,563 |
| Ketoconazole | 290 | $3,829 |
| Betamethasone Valerate | 105 | $3,100 |
| Metronidazole | 65 | $3,015 |
| ValacyclovirValacyclovir Hcl | 34 | $2,272 |
| Mupirocin | 320 | $2,143 |
| CiclopiroxCiclopirox Olamine | 110 | $1,883 |
| Hydrocortisone | 246 | $1,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,773 | $176,27013 claims |
| Almirall LLCSeysara | $20,577 | $11,07811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 475 dermatology providers in North Carolina.
Other dermatology in Charlotte
- Gary SlaughterCharlotte$55K
- Christopher SnyderCharlotte$24K
- Marc DarstCharlotte$19K
- Martie PriceCharlotte$15K
- Steven FeldmanWinston Salem$3.4M
- Nicole SeminaraHuntersville$1.4M
- Andrew LeeElkin$702K
- Christopher SayedChapel Hill$690K
- William HooverConcord$594K
- George MagelHickory$554K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.